View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 6, 2020

True North acquires 3% stake in Biologics India for $100m

Private equity fund True North has acquired 3% stake in Biologics India (BBIL) for nearly $100m, reported The Economic Times.

Private equity fund True North has acquired 3% stake in Biologics India (BBIL) for nearly $100m, reported The Economic Times.

Following the True North investment, the Biocon-subsidiary now values around Rs250bn ($3bn- $3.5bn), the report added citing two people familiar with the development.

This also forms a portion of BBIL’s more comprehensive fundraising round expected to close by the middle of this year.

A formal announcement of the transaction is expected later this week. However, True North and Biocon did not confirm the deal to The Economics Times queries.

Currently, Biocon is in talks with Singapore’s Temasek Holdings and the UK Government’s investment arm CDC for additional investments in the subsidiary.

Biocon established BBIL in 2017 to host its biologics business, biosimilars that feature monoclonal antibodies, novel biologics and recombinant insulins. As the name suggests, biosimilars are highly similar to another licenced biologic medicine called reference product.

BBIL is said to be one of the fastest-growing divisions within Biocon. The division aims to achieve revenue of $1bn in the financial year 2022.

In 2018, Biocon, along with its partner Mylan, secured approval from the US Food and Drug Administration (FDA) for fulphila, a biosimilar to neulasta.

Fulphila minimises the febrile neutropenia duration in some cancer patients undergoing chemotherapy. The US regulator approved the biosimilar following a review of analytical, non-clinical and clinical data.

Later, Biocon secured FDA green light to start manufacturing fulphila in its facility in Bengaluru.

Biocon also received the FDA approval for another biosimilar called Trastuzumab.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology